DALLAS / Jun 16, 2025 / Business Wire / Lantern Pharma Inc . (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR ® AI platform, today announces remarkable clinical observations for a patient in Lantern’s Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in... Read More